Investigational drug · Phase 3
ICP-332
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non Segmental Vitiligo, Chronic Spontaneous Urticaria (CSU), Atopic Dermatitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
8
Any phase or sponsor naming "ICP-332"
First trial start
2024
Nov 14, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ICP-332", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non Segmental Vitiligo
- Chronic Spontaneous Urticaria (CSU)
- Atopic Dermatitis
- Plaque Psoriasis
Approved drugs for the same conditions: Plaque psoriasis · Atopic dermatitis (eczema) · Chronic hives (urticaria) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "ICP-332" as an intervention, largest first.
- ICP-332 in Subjects With Non-segmental VitiligoPivotal-lookingRecruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT07047612 · 603 participants (planned) · Start May 9, 2025 · Primary completion Apr 2029
Drug: ICP-332 Tablets; ICP-332 Placebo Tablets · For: Non Segmental Vitiligo
Sites: Wuhu, China; Beijing, China; Chongqing, China · 45 sites in all
- ICP-332 in Subjects With Moderate to Severe Atopic DermatitisPivotal-lookingRecruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT06775860 · 552 participants (planned) · Start Nov 14, 2024 · Primary completion Nov 25, 2026
Drug: ICP-332 Tablets; ICP-332 Placebo Tablets · For: Atopic Dermatitis
Sites: Hefei, China; Wuhu, China; Beijing, China · 62 sites in all
- Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous UrticariaPivotal-lookingRecruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT07378527 · 344 participants (planned) · Start Feb 13, 2026 · Primary completion Sep 2028
Drug: ICP-332 Tablets; ICP-332 placebo Tablets and 1 more · For: Chronic Spontaneous Urticaria (CSU)
Sites: Bengbu, China; Wuhu, China; Beijing, China · 30 sites in all
- Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT07251998 · 182 participants · Start Dec 22, 2025 · Primary completion Oct 30, 2026
Drug: ICP-332 Tablets; ICP-332 Tablets and 1 more · For: Plaque Psoriasis
Sites: Wuhu, China; Beijing, China; Chongqing, China · 22 sites in all
- Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo NodularisPivotal-lookingRecruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT07236099 · 135 participants (planned) · Start Nov 27, 2025 · Primary completion Mar 2027
Drug: ICP-322; Placebo · For: Prurigo Nodularis (PN)
Sites: Birmingham, Alabama; Phoenix, Arizona; Fremont, California · 43 sites in all
- Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic DermatitisStatus unknown
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT05702268 · 75 participants (planned) · Start Mar 18, 2023 · Primary completion Jul 30, 2023
Drug: ICP-332; ICP-332 Placebo · For: Moderate to Severe Atopic Dermatitis
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 28 sites in all
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT05399030 · 72 participants · Start Aug 14, 2021 · Primary completion Jan 30, 2022
Drug: ICP-332 · For: Healthy Subjects
Sites: Jinan, China
InnoCare Pharma Inc.Industry
NCT06530966 · 24 participants · Start Jul 23, 2024 · Primary completion Nov 8, 2024
Drug: ICP-332 Tablets; ICP-332 Placebo Tablets · For: Healthy Subjects
Sites: Baltimore, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Safety, pharmacokinetics and pharmacodynamics of ICP-332, an oral TYK2 inhibitor, in healthy participants: a randomized, double-blind, placebo-controlled phase I study.
Zhao H, Wei Y, Jiang Y, et al. · Front Pharmacol 2026
- Safety and Efficacy of ICP-332 for Moderate to Severe Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
Xu J, Zhang L, Liang Y, et al. · JAMA Dermatol 2026
- Recent progress in tyrosine kinase 2 inhibitors for atopic dermatitis.
Liu Q, Xia Y, Liu L, et al. · Expert Opin Investig Drugs 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.